Clarus Wealth Advisors Invests $207,000 in Humacyte, Inc. (NASDAQ:HUMA)

Clarus Wealth Advisors bought a new stake in Humacyte, Inc. (NASDAQ:HUMA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 41,063 shares of the company’s stock, valued at approximately $207,000.

Several other hedge funds have also recently made changes to their positions in HUMA. Private Advisor Group LLC grew its stake in Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after purchasing an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after purchasing an additional 8,557 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Humacyte by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after buying an additional 8,965 shares during the last quarter. Brookstone Capital Management purchased a new stake in Humacyte in the fourth quarter valued at approximately $56,000. Finally, XTX Topco Ltd increased its holdings in Humacyte by 48.8% in the 3rd quarter. XTX Topco Ltd now owns 34,049 shares of the company’s stock worth $185,000 after buying an additional 11,172 shares during the period. 44.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HUMA has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. TD Cowen reissued a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. Finally, D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Monday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $13.71.

Insider Buying and Selling at Humacyte

In related news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This trade represents a 13.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,500,000 shares of company stock valued at $6,606,799. Company insiders own 11.20% of the company’s stock.

Humacyte Price Performance

NASDAQ:HUMA opened at $4.12 on Wednesday. The stock has a market capitalization of $518.54 million, a PE ratio of -3.07 and a beta of 1.32. Humacyte, Inc. has a 52 week low of $2.48 and a 52 week high of $9.97. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The stock’s 50-day moving average price is $4.64 and its 200-day moving average price is $5.68.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.